Respiratory Therapeutics Market to Amount to USD 41.3 Bn by 2023, Forecasts GBI Research in Its New Topical Report Available at MarketPublishers.com
20 Oct 2017 • by Natalie Aster
LONDON – The respiratory therapy area encompasses a range of indications affecting the respiratory system in various ways, for instance, inflammation, excessive production of mucus in the airways and scarring of lung tissue. Idiopathic pulmonary fibrosis (IPF), asthma, cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) are amid the most common respiratory disorders worldwide. The causes of respiratory diseases vary considerably across each indication and comprise factors like occupation, environment, age, genetic predisposition, etc.
The therapeutics landscape for respiratory diseases has traditionally been led by small molecule therapies that target the disease symptoms instead of the underlying cause. However, treatment options for respiratory disorders have developed significantly during the past decade, a range of new and targeted therapies has entered the market.
At present, around 937 products are being actively developed in the respiratory drug pipeline. The pipelines of IPF, COPD, CF and asthma contains 79, 106, 131 and 261 products, respectively.
Though more traditional non-specific symptomatic therapies still continue to have a strong presence in the respiratory disorders pipeline, there are also a number of promising targeted biologic therapies.
In 2016, the respiratory therapeutics market has reached the value of USD 30.9 billion. The market value will likely amount to USD 41.3 billion by 2023.
New topical research study “Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers” drawn up by GBI Research provides profound insights into the current treatment landscape, gives all-round portfolios of major marketed products, examines historical and forecast sales patterns, presents an insightful analysis of each drug’s mechanism of action. Besides, this publication includes an all-round assessment of the respiratory pipeline on the basis of stage of development, molecular target and molecule type. It also gives relevant data on clinical trials and identifies the key risk factors associated with efforts to bring pipeline products to the market. This report not only describes the historical background and actual scenario, but also points out the future growth opportunities and challenges, as well as provides access to future forecasts up to 2023. It examines how new drug entries, patent expirations and epidemiology trends are expected to influence the respiratory therapeutics market development in the coming years, points out lucrative commercial opportunities, gives forecasts through 2023, etc.
A full collection of the publisher’s research studies is provided in GBI Research catalogue.